Press release
Age-related Macular Degeneration Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034
Age-related Macular Degeneration Market
[Nevada, United States] - DelveInsight's "Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Age-related Macular Degeneration, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
To Know in detail about the Age-related Macular Degeneration Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Key Findings from the Age-related Macular Degeneration Market Report:
• The Age-related Macular Degeneration market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Hoffmann-La Roche announced that results of their Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinal in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)
• In October, 2024: Novartis Pharmaceuticals announced a 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients With Neovascular Age Related Macular Degeneration (TALON)
• In October, 2024: Genentech, Inc. announced a Phase IV, Multicenter, Open-Label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-Related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)
• In October, 2024: Janssen Research & Development, LLC announced a Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
• In October, 2024: AbbVie announced that their randomized, partially masked, controlled, Phase 3 clinical study will evaluate the efficacy and safety of ABBV-RGX-314 gene therapy in participants with nAMD. The study will evaluate 2 dose levels of RGX-314 gene therapy relative to an active comparator. The primary endpoint of this study is mean change in best-corrected visual acuity (BCVA) of ABBV-RGX-314 relative to aflibercept. Approximately 660 participants who meet the inclusion/exclusion criteria, will be enrolled into one of 3 arms.
• As per our estimation, in 2021, the Age-related Macular Degeneration Market Size was approximately USD 1,377 million, and of Wet AMD was approximately USD 8,463 million which is further expected to increase by 2034.
• The Age-related Macular Degeneration market size in seven major markets is segregated into two part, Dry-AMD, and Wet-AMD. As per our analysis and estimation, in 2021, the Age-related Macular Degeneration market size was approximately USD 9,840 million which is further expected to increase by 2034.
• In the 7MM, the analysis of type-specific cases of AMD revealed that there were approximately 3,880,752 and 34,926,768 cases of Wet-AMD and Dry-AMD, respectively in the year 2021. These cases are expected to increase by multiple folds by 2034.
• Key Age-related Macular Degeneration Companies are as follows: Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics
• Key Age-related Macular Degeneration Therapies are as follow: Eylea (aflibercept), Beovu (brolucizumab), Lucentis (ranibizumab), OPT-302, KSI-301, RGX-314, Danicopan (ALXN2040), EG-301, JNJ-81201887, ABBV-RGX-314, Ranibizumab: Genentech, Aflibercept, pegaptanib sodium
• Launching multiple stage Age-related Macular Degeneration pipeline products is expected to revolutionize market dynamics, further propelling market growth.
Dive into our detailed Age-related Macular Degeneration market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Age-related Macular Degeneration Overview:
Age-related Macular Degeneration (AMD) is the leading cause of blindness in elderly patients in developed communities. It is an eye disease of elderly individuals that causes a progressive loss of the central vision needed to drive, read, recognize faces, and see the world in color. AMD's progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life.
Age-related Macular Degeneration Epidemiology Segmentation:
The Age-related Macular Degeneration market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Age-related Macular Degeneration Total Diagnosed Prevalent Cases
• Age-related Macular Degeneration Type-specific Diagnosed Cases
• Age-related Macular Degeneration Total Age-specific Cases
• Age-related Macular Degeneration Total Geographic Atrophy Cases
For more information about Age-related Macular Degeneration companies working in the treatment market, visit https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Age-related Macular Degeneration Market Insights
Age-related Macular Degeneration (AMD) is a chronic, progressive eye disorder and one of the leading causes of vision loss in adults over the age of 50, especially in developed countries. It primarily affects the macula, the central part of the retina responsible for clear central vision, and manifests in two main forms:
Age-related Macular Degeneration Drugs Uptake
• Ranibizumab (Lucentis): One of the pioneering anti-VEGF agents, it helps control abnormal blood vessel growth and leakage by blocking VEGF. Typically administered via monthly intravitreal injections.
• Aflibercept (Eylea): Another major anti-VEGF drug, offering less frequent dosing compared to Lucentis. It also binds to other growth factors in addition to VEGF, potentially offering broader efficacy.
• Bevacizumab (Avastin): While primarily a cancer drug, Avastin is widely used off-label for wet AMD due to its lower cost compared to Lucentis and Eylea, despite requiring more frequent dosing.
• Faricimab (Vabysmo): Approved in 2022, this drug targets both VEGF and angiopoietin-2, offering a potential advancement in efficacy and durability over current anti-VEGF treatments.
Age-related Macular Degeneration Emerging Therapies
• Pegcetacoplan (Syfovre): The first treatment approved for geographic atrophy (an advanced form of dry AMD), targeting C3, a component of the complement pathway, which is implicated in the disease's progression.
• Gene Therapy: Companies like Gyroscope Therapeutics and Adverum Biotechnologies are developing gene therapies aimed at reducing the need for frequent injections and potentially providing long-lasting efficacy in both dry and wet AMD.
Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Age-related Macular Degeneration Therapies and Key Companies:
• Eylea (aflibercept): Regeneron Pharmaceuticals
• Beovu (brolucizumab): Novartis
• Lucentis (ranibizumab): Roche
• OPT-302: Opthea Limited
• KSI-301: Kodiak Sciences Inc.
• RGX-314: Regenxbio
• Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca
• EG-301: Evergreen Therapeutics
• JNJ-81201887: Janssen Research & Development, LLC
• ABBV-RGX-314: AbbVie
• Ranibizumab: Genentech, Inc.
• Aflibercept: Bayer
• pegaptanib sodium: Pfizer
Age-related Macular Degeneration Epidemiology:
Age-related macular degeneration (AMD) is one of the leading causes of vision loss globally, particularly among older adults. The prevalence of AMD is strongly linked to age, with incidence rates rising significantly in individuals over 50.
• AMD affects approximately 196 million people worldwide as of 2020, and this number is expected to rise to 288 million by 2040 due to the aging global population.
• It is the leading cause of irreversible blindness in developed countries, particularly in populations aged 50 years and older.
• In Europe, AMD accounts for 8.7% of all blindness cases, and its prevalence is expected to increase due to demographic shifts towards older populations.
Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Age-related Macular Degeneration Market Drivers:
• Growing Aging Population
• Advancements in Anti-VEGF Therapies
• Pipeline Expansion for Dry AMD
• Rising Healthcare Expenditure and Awareness
Age-related Macular Degeneration Market Barriers:
• High Treatment Costs
• Frequent Injections and Patient Compliance
• Limited Treatment Options for Dry AMD
• Adverse Events and Safety Concerns
Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Scope of the Age-related Macular Degeneration Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Age-related Macular Degeneration Companies: Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics
• Key Age-related Macular Degeneration Therapies: Eylea (aflibercept), Beovu (brolucizumab), Lucentis (ranibizumab), OPT-302, KSI-301, RGX-314, Danicopan (ALXN2040), EG-301, JNJ-81201887, ABBV-RGX-314, Ranibizumab: Genentech, Aflibercept, pegaptanib sodium
• Age-related Macular Degeneration Therapeutic Assessment: Current marketed and emerging therapies
• Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Age-related Macular Degeneration Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.
To access the full report and gain a deeper understanding of Age-related Macular Degeneration market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr
Table of Content:
1. Key Insights
2. Report Introduction
3. Wet AMD Market Overview at a Glance
4. Dry AMD Market Overview at a Glance
5. Wet AMD Market: Future Perspective
6. Executive Summary
7. Key Events
8. Disease Background and Overview
9. Epidemiology and Patient Population
10. Age-related Macular Degeneration Patient Journey
11. Marketed Age-related Macular Degeneration Drugs
12. Emerging Drugs of Wet AMD
13. Emerging Drugs of Dry AMD
14. Age-related Macular Degeneration Market Analysis: Seven Major Markets
15. Key Opinion Leaders' Views
16. Age-related Macular Degeneration Market Drivers
17. Age-related Macular Degeneration Market Barriers
18. SWOT Analysis
19. Age-related Macular Degeneration Market Access and Reimbursement
20. Unmet Needs
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.
Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Age-related Macular Degeneration Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034 here
News-ID: 3705031 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Age
Dark Age Defense Survival Guide
Get Dark Age Defense For A Very Special Price >> https://rebrand.ly/2f043b
People should know how to keep themselves and their families safe, especially in times like this where there is a high probability of natural disasters, power blackouts, wars, and other severe conditions.
The Dark Age Defense is a digital survival aid that provides users with detailed information on various topics including how to create electricity and keep your household appliances…
Adult Milk Powder Market Introducing New Industry Dynamics Through Swot Analysis …
LOS ANGELES, UNITED STATES - The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Adult Milk Powder market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Adult Milk Powder Market. We have provided deep analysis of…
Tattoo Ink Market Size, By Type (Black & Grey Tattoo Ink, Colour Tattoo Ink), By …
Global demand for tattoo ink market was valued at approximately USD 80 million in 2018 and is expected to generate revenue of around USD 142 million by end of 2025, growing at a CAGR of around 5.7% between 2019 and 2025.
A recent market research report added to repository of Credible Markets is an in-depth analysis of Global Tattoo Ink Market. On the basis of historic growth analysis and current…
Age Discrimination
Age Discrimination looks at how both young and old can be penalised by prejudice against their age group. This comprehensive new book is essential to practitioners responsible for HR issues, finance, operations, service delivery, quality and customer relations, and for those with a policy focus or academic interest in diversity issues.
Gower is recognised as one of the world's leading publishers of specialist business and management books and resources. Our publishing…
Victorian Age Meets Digital Age
The digital age is entering the elegant Victorian age Eurocentres school building. In some classrooms interactive whiteboards have been installed and are now being intensively used with language students from all over the world.
The interactive whiteboards have been helping classes become much more exciting and closer to real life. This user-friendly technology enables students to better engage with and discuss up-to-date news or life-style features, enjoy playful grammar exercises,…
PerTOOLS Enter The Video Age
Today in London, PerTOOLS, the provider of Time Series Analysis and Data Extractor tools launched their new website complete with Video Demonstrations of all their products. The PerTOOLS approach has always been to help clients understand PerTOOLS products and that is the reason why PerTOOLS offer free trials - to allow people to experience the tools with no commitment. The addition of Video Demonstrations to the PerTOOLS website will go…
